FY2025 · ended Dec 31, 2025 · Revenue $262.60M, -0.3% YoY · Filed Feb 24, 2026
Arvinas, Inc. (ARVN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $262.6 million and a net loss of $80.8 million. Free cash flow was -$275.7 million. As of Sep 30, 2026 it held $558.4 million in cash and investments and $7.6 million in total debt.
Revenue (TTM)
$275.30M
-11.8% vs year-ago TTM
Net income (TTM)
$-9.50M
+83.8% vs year-ago TTM
Operating cash flow (TTM)
$-158.30M
+51.7% vs year-ago TTM
Free cash flow (TTM)
$-159.80M
+51.5% vs year-ago TTM
EPS (TTM)
$-0.14
+82.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
63.96M
-7.0% vs prior year
Net cash
$550.80M
as of Sep 30, 2026
Operating margin
-12.1%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ARVN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Accelerated filer
- SEC CIK
- 1655759
- Former names
- ARVINAS INC. (until Oct 10, 2018); ARVINAS HOLDING COMPANY, LLC (until Sep 28, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $262.6M | $263.4M | $78.5M | $131.4M | $53.6M |
| Operating income | -$118.5M | -$250.2M | -$401.5M | -$263.2M | -$188.4M |
| Net income | -$80.8M | -$198.9M | -$367.3M | -$282.5M | -$191.0M |
| Diluted EPS | -$1.14 | -$2.77 | -$6.62 | -$5.31 | -$3.82 |
| Operating cash flow | -$273.8M | -$259.3M | -$347.8M | -$273.5M | $559.4M |
| Free cash flow | -$275.7M | -$261.1M | -$350.7M | -$280.3M | $554.7M |
| Total assets | $717.9M | $1.1B | $1.3B | $1.3B | $1.6B |
| Total liabilities | $284.0M | $529.7M | $644.6M | $703.9M | $799.9M |
| Stockholders' equity | $433.9M | $561.7M | $660.0M | $564.9M | $781.7M |
| Cash and investments | $685.4M | $1.0B | $1.3B | $1.2B | $1.5B |
| Total debt | $9.1M | $9.9M | $3.4M | $5.5M | $5.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 3, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 22, 2026 | Jun 22, 2026 |
All 602 Arvinas, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.